Dr. Marc Siegel says a new experimental pill developed to treat COVID-19 could be the “holy grail of therapeutics” used against the virus. First-stage testing of Molnupiravir, developed by Merck and Ridgeback Biotherapeutics, showed promising signs of effectiveness in reducing the virus in patients.
